Valuation: Micromedic Technologies Ltd

Market Cap 26.25M 0 8.56M 7.44M 6.93M 6.36M 12.01M 817M 12.2M 81.66M 32.05M 407M 32.15M 31.45M 1.36B P/E 2023
-2.52x
P/E 2024 -7.86x
Enterprise Value 26.21M 0 8.55M 7.43M 6.92M 6.35M 11.99M 816M 12.18M 81.52M 32M 406M 32.1M 31.4M 1.36B EV / Sales 2023
-
EV / Sales 2024 57.4x
Free-Float
30.21%
Yield 2023 *
-
Yield 2024 -
Manager TitleAgeSince
Chief Executive Officer 42 12/08/2020
Director of Finance/CFO 63 10/07/2022
General Counsel 55 12/08/2020
Director TitleAgeSince
Chairman 87 21/11/2011
Director/Board Member 76 13/10/2014
Director/Board Member 71 12/08/2020
Change 5-day change 1-year change 3-year change Capi.($)
+5.37%+92.48% - - 4.2M
-22.52%-18.18%+97.02%+68.74% 3.69B
-6.66%+1.35%+120.41%+167.42% 3.59B
-13.22%-18.44%+58.37%-43.94% 1.82B
+3.44%+4.55%-28.26%-36.48% 2.17B
+14.72%+17.69%+255.80%+300.64% 2.26B
-2.67%-2.81%+180.77%-41.91% 969M
+6.96%-1.82%-9.43%+15.45% 853M
+1.29%+6.41%-37.76%-14.48% 511M
+7.90%-3.22%-2.47% - 449M
Average -0.54%-2.86%+70.50%+51.93% 1.81B
Weighted average by Cap. -5.07%-3.69%+95.63%+84.49%

Financials

2023 2024
Net sales 876K 0 286K 248K 231K 212K 401K 27.27M 407K 2.73M 1.07M 13.58M 1.07M 1.05M 45.53M 413K 0 135K 117K 109K 100K 189K 12.86M 192K 1.28M 504K 6.4M 506K 495K 21.47M
Net income -3.88M -0 -1.27M -1.1M -1.02M -940K -1.77M -121M -1.8M -12.07M -4.74M -60.13M -4.75M -4.65M -202M -3.28M -0 -1.07M -931K -866K -795K -1.5M -102M -1.53M -10.21M -4.01M -50.89M -4.02M -3.93M -171M
Net Debt -101K -0 -32.94K -28.64K -26.65K -24.47K -46.21K -3.14M -46.93K -314K -123K -1.57M -124K -121K -5.25M -43K -0 -14.02K -12.19K -11.35K -10.42K -19.67K -1.34M -19.98K -134K -52.5K -667K -52.67K -51.51K -2.23M
Logo Micromedic Technologies Ltd
Nextage Therapeutics Ltd, formerly known asMicromedic Technologies Ltd,is an Israel-based company engaged in the development and commercialization of cancer diagnostic products. Its portfolio includes a range of cancer and cancer-related indications including colorectal cancer, breast cancer, cervical cancer, bladder cancer, lung cancer, and diagnostic tools for personalized treatment. Micromedic forms a cluster that manages the development of a variety of products across the cancer diagnostic value chain. From screening and risk identification, through diagnostics, personalized medicine, and monitoring disease recurrence, Micromedic identifies projects that fill unmet needs in various cancer related indications, and turns them into viable marketable products. Micromedic operates through strategic collaborations and in-licensing from scientific institutes world-wide as well as in-house based research.
Employees
-